Chemotherapy denials: 41.4% overturned by independent reviewers
In 263 California IMR decisions from 2002 to 2021, reviewers overturned the plan 109 times (41.4%). In the last five years: 28.6% of 14. Denials reach IMR only when a member appeals all the way; read the caveats below before generalising.
By diagnosis
| Diagnosis category | Decisions | Overturned | Last 5 years |
|---|---|---|---|
| Cancer | 252 | 40.9% | 23.1% of 13 |
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 14 | 28.6% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 73 | 31.5% | 41.4% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 36 | 30.6% | 41.4% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 29 | 37.9% | 41.4% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 27 | 37.0% | 41.4% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 19 | 42.1% | 41.4% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 15 | 53.3% | 41.4% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 9 | 11.1% | 41.4% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: An enrollee has requested authorization and coverage for Mekinist tablets once a day. Findings: The physician reviewer found that AVM is a rare, congenital vascular growth that progresses throughout life, causing complications that include bleeding, functional deficits, deformity, and high-output cardiac failure. Traditional management with embolization or surgical resection, with or without embolization, carries a …”
“Nature of Statutory Criteria/Case Summary: The patient has requested reimbursement for radiation therapy services. Findings: The physician reviewer found that atient is noted to have moderately differentiated estrogen receptor (ER) positive, progesterone receptor (PR) positive, invasive ductal carcinoma with micropapillary features. She underwent treatment with surgery and intraoperative radiation therapy (IORT). The records provided for review support that this patient …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Tbo-filgrastim (Granix), 1 microgram injections (J1447). Findings: The physician reviewer found that white blood count growth factors are supported to reduce a patient’s risk of neutropenic fever when the anticipated risk of neutropenic fever for a chemotherapy regimen is approximately 20% (Smith, et al.). This patient’s records …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Chemotherapy denials overturned?
In 263 California IMR decisions from 2002 to 2021, reviewers overturned the plan 109 times (41.4%). In the last five years: 28.6% of 14.
What did the reviewers' findings mention in overturned cases?
The table on this page counts keyword matches in the findings: prior therapies tried, contraindications, guidelines cited, published evidence, whether the records supported the request. They describe what the findings say, not why the case was decided.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but the reasoning is the same kind: criteria, documentation and alternatives. Use the findings as a guide to what to document.
Related: California appeal rights · California external-review reversal rate · The levers library · CSV
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.